BTX

Brooklyn ImmunoTherapeutics, Inc. [BTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BTX Stock Summary

In the News

08:00 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences:

04:15 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

Ticker Symbol to Remain “BTX” Ticker Symbol to Remain “BTX”

04:30 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyn's common stock (the “Time-Based Option”) and a restricted stock unit covering 80,650 shares of Brooklyn's common stock (the “RSU”).

10:07 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021.

08:30 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience's Co-founder and Chief Executive Officer.

08:15 28 Mar 2024 BTX

Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts

CAMBRIDGE, Mass., Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts, celebrated its tenth anniversary on September 9, 2021 with the grand opening of its new ISO Class 7 cleanroom facility at its headquarters near Inman Square.

04:15 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that its 2021 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held at 9 a.m., Eastern time, on August 20, 2021, was convened and adjourned, without any business being conducted, due to lack of the required quorum.

08:30 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021

NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D. on August 19, 2021.

04:15 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET

BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it will host a shareholder update conference call on Thursday, August 19, 2021, at 4:30 p.m. ET.

02:22 28 Mar 2024 BTX

Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021

NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the SNN Virtual Investor Conference being held August 17 – 19, 2021.

BTX Financial details

Company Rating
Neutral
Market Cap
1.05M
Income
-21.67M
Revenue
68K
Book val./share
0.41
Cash/share
1.4
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
09 Nov 2022
P/E
-0.47
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.79
P/C
2.71
P/FCF
-0.46
Quick Ratio
1.5
Current Ratio
1.79
Debt / Equity
4.03
LT Debt / Equity
3.03
-
-
EPS (TTM)
-4.08
EPS next Y
-
EPS next Q
-
EPS this Y
-49.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-32.2%
Revenue last 5Y
-67.85%
Revenue Q/Q
-66.67%
EPS Q/Q
10.68%
-
-
-
-
SMA20
-13.81%
SMA50
17.42%
SMA100
-
Inst Own
1.18%
Inst Trans
0%
ROA
-92%
ROE
-155%
ROC
-1.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
5.13M
Shs Float
1.68M
-
-
-
-
Target Price
-
52W Range
0.181-200.0
52W High
-
52W Low
-
RSI
38.12
Rel Volume
0.24
Avg Volume
85.43K
Volume
20.64K
Perf Week
-21.85%
Perf Month
13.44%
Perf Quarter
-
Perf Half Y
20.26%
-
-
-
-
Beta
0.78748
-
-
Volatility
0.27%, 0.48%
Prev Close
-1.3%
Price
3.8001
Change
-9.09%

BTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
275.560000.01
Net income per share
-28.485.74-56.49-8.06-4.08
Operating cash flow per share
38.18-3.9-10.85-6.88-3.84
Free cash flow per share
22.96-3.92-10.92-6.97-3.84
Cash per share
45.340.797.853.751.43
Book value per share
70.833.6933.970.42
Tangible book value per share
61.15-0.18-1.113.30.04
Share holders equity per share
70.833.6933.970.42
Interest debt per share
88.061.421.291.371.81
Market cap
6.33M185.98M180.56M9.82M9.57M
Enterprise value
9.15M187.25M166.3M2.52M43.83M
P/E ratio
-3.0915.62-1.48-0.4-0.44
Price to sales ratio
0.32000140.66
POCF ratio
2.31-22.96-7.69-0.47-0.47
PFCF ratio
3.83-22.85-7.64-0.46-0.47
P/B Ratio
1.2424.2827.770.814.28
PTB ratio
1.2424.2827.770.814.28
EV to sales
0.46000644.61
Enterprise value over EBITDA
4.68-26.192.42-0.08-2.24
EV to operating cash flow
3.33-23.11-7.08-0.12-2.15
EV to free cash flow
5.54-23-7.03-0.12-2.15
Earnings yield
-0.320.06-0.68-2.5-2.27
Free cash flow yield
0.26-0.04-0.13-2.17-2.14
Debt to equity
1.190.380.420.344.03
Debt to assets
0.40.220.080.190.18
Net debt to EBITDA
1.44-0.18-0.210.23-1.75
Current ratio
10.555.11.791.46
Interest coverage
-4.87-168.56923.54-1.11K-33.67
Income quality
-1.341.110.190.850.94
Dividend Yield
00000
Payout ratio
-0.010000
Sales general and administrative to revenue
0000214.5
Research and developement to revenue
000087.06
Intangibles to total assets
0.050.620.270.090.04
Capex to operating cash flow
-0.400.010.010
Capex to revenue
-0.06000-0.28
Capex to depreciation
-0.35-0.4-0.34-0.6-0.02
Stock based compensation to revenue
000018.26
Graham number
213.0521.8261.7826.826.21
ROIC
-0.090.935.72-1.91-0.47
Return on tangible assets
-0.142.44-5.2-1.21-0.46
Graham Net
-76.31-1.74-3.890.5-7.34
Working capital
-25K-1.39M15.09M6.03M3.03M
Tangible asset value
4.4M-375K-2.4M10.06M189K
Net current asset value
-4.12M-3.52M-7.16M3.51M-37.3M
Invested capital
1.190.380.420.344.03
Average receivables
0597.5K342K817.5K688K
Average payables
01.06M1.52M1.69M1.34M
Average inventory
0545K0-475.5K-475.5K
Days sales outstanding
22.020002.28K
Days payables outstanding
38.864.75K1.4K1.19K286.57
Days of inventory on hand
50.7300-698.420
Receivables turnover
16.570000.16
Payables turnover
9.390.080.260.311.27
Inventory turnover
7.200-0.520
ROE
-0.41.55-18.81-2.03-9.7
Capex per share
-15.22-0.02-0.07-0.10

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.010
Net income per share
-1.24-1.06-0.85-1.03-1.14
Operating cash flow per share
-1.5-1.18-0.73-1.08-0.86
Free cash flow per share
-1.5-1.18-0.73-1.08-0.87
Cash per share
3.151.050.350.841.4
Book value per share
3.331.440.730.660.41
Tangible book value per share
2.771.040.340.280.03
Share holders equity per share
3.331.440.730.660.41
Interest debt per share
1.140.717.027.641.73
Market cap
11.69M17.43M11.98M11.79M9.74M
Enterprise value
4.38M15.56M47.36M48.48M44.01M
P/E ratio
-0.65-0.8-0.66-0.53-0.4
Price to sales ratio
000231.25572.82
POCF ratio
-2.15-2.88-3.1-2.02-2.09
PFCF ratio
-2.14-2.88-3.1-2.02-2.08
P/B Ratio
0.972.363.13.314.36
PTB ratio
0.972.363.13.314.36
EV to sales
000950.682.59K
Enterprise value over EBITDA
-0.87-3.02-12.25-9.72-8.33
EV to operating cash flow
-0.81-2.57-12.23-8.32-9.44
EV to free cash flow
-0.8-2.57-12.23-8.32-9.4
Earnings yield
-0.38-0.31-0.38-0.47-0.63
Free cash flow yield
-0.47-0.35-0.32-0.49-0.48
Debt to equity
0.340.489.6311.584.03
Debt to assets
0.190.230.790.790.18
Net debt to EBITDA
1.450.36-9.15-7.36-6.49
Current ratio
1.791.210.540.731.46
Interest coverage
-789.5-50.630-48.29-14.86
Income quality
1.211.120.861.040.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00078.02265.06
Research and developement to revenue
00028.5771.18
Intangibles to total assets
0.090.140.040.040.04
Capex to operating cash flow
00000
Capex to revenue
0000-1.12
Capex to depreciation
-0.24000-0.04
Stock based compensation to revenue
0003.419.71
Graham number
9.635.853.733.913.25
ROIC
-0.27-0.45-0.06-0.07-0.13
Return on tangible assets
-0.22-0.41-0.1-0.11-0.13
Graham Net
0.42-0.36-7.64-7.91-7.21
Working capital
6.03M1.11M-3.27M-2.6M3.03M
Tangible asset value
10.06M5.34M1.82M1.52M189K
Net current asset value
3.51M-1.21M-39.2M-41.66M-37.3M
Invested capital
0.340.489.6311.584.03
Average receivables
938.5K799K815.5K1.38M1.1M
Average payables
1.39M1.54M2.07M2.07M1.27M
Average inventory
-475.5K-475.5K000
Days sales outstanding
0003.13K2.25K
Days payables outstanding
1.7K2.12K3.82K1.1K175.56
Days of inventory on hand
-995.230000
Receivables turnover
0000.030.04
Payables turnover
0.050.040.020.080.51
Inventory turnover
-0.090000
ROE
-0.37-0.73-1.17-1.57-2.76
Capex per share
-0.010000

BTX Frequently Asked Questions

What is Brooklyn ImmunoTherapeutics, Inc. stock symbol ?

Brooklyn ImmunoTherapeutics, Inc. is a US stock , located in Carlsbad of California and trading under the symbol BTX

What is Brooklyn ImmunoTherapeutics, Inc. stock quote today ?

Brooklyn ImmunoTherapeutics, Inc. stock price is $3.8001 today.

Is Brooklyn ImmunoTherapeutics, Inc. stock public?

Yes, Brooklyn ImmunoTherapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap